Market Pulse Archives

Oct. 6, 2020, 10:04 a.m. EDT

Vir's stock rises as COVID-19 drug moves to late-study clinical trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Vir Biotechnology Inc. (VIR)
  • X
    GlaxoSmithKline PLC ADR (GSK)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Vir Biotechnology Inc. /zigman2/quotes/214486077/composite VIR -4.95% gained 5.3% in trading on Tuesday after the company said it is expanding the Phase 3 clinical trial for an experimental COVID-19 treatment. The treatment, a monoclonal antibody called VIR-7831, is aimed at patients with COVID-19 who are at high risk of hospitalization. The randomized, placebo-controlled late-stage study will evaluate 1,300 non-hospitalized patients who have tested positive for COVID-19 and whether they need to be hospitalized or die within 29 days. Results are expected in January. GlaxoSmithKline /zigman2/quotes/209463850/composite GSK +1.21% is also involved in the development of the therapy, as part of a coronavirus-focused development agreement announced by Vir and GSK in April. Vir's stock has soared 211.0% so far this year. The S&P 500 /zigman2/quotes/210599714/realtime SPX +0.18% , in comparison, has gained 5.5%.

/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 46.06
-2.40 -4.95%
Volume: 223,221
April 21, 2021 9:54a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$6.20 billion
Rev. per Employee
$233,541
loading...
/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 38.16
+0.45 +1.21%
Volume: 444,413
April 21, 2021 9:55a
P/E Ratio
13.09
Dividend Yield
5.25%
Market Cap
$92.33 billion
Rev. per Employee
$464,855
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,142.33
+7.39 +0.18%
Volume: 252.34M
April 21, 2021 9:55a
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.